BR9510490B1 - composição farmacêutica combinada de dois componentes estruturada para uso em um hospedeiro. - Google Patents

composição farmacêutica combinada de dois componentes estruturada para uso em um hospedeiro.

Info

Publication number
BR9510490B1
BR9510490B1 BRPI9510490-9A BR9510490A BR9510490B1 BR 9510490 B1 BR9510490 B1 BR 9510490B1 BR 9510490 A BR9510490 A BR 9510490A BR 9510490 B1 BR9510490 B1 BR 9510490B1
Authority
BR
Brazil
Prior art keywords
host
enzyme
prodrug
component
natural
Prior art date
Application number
BRPI9510490-9A
Other languages
English (en)
Other versions
BR9510490A (pt
Inventor
Christopher John Taylorson
Hendrikus Johannes Eggelte
Antonio Tarragona-Fiol
Brian Robert Rabin
Francis Thomas Boyle
John Frederick Hennam
David Charles Blakey
Peter Robert Marsham
David William Heaton
David Huw Davies
Anthony Michael Slater
Laurent Francois Andre Hennequin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9510490(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9426192.2A external-priority patent/GB9426192D0/en
Priority claimed from GBGB9516810.0A external-priority patent/GB9516810D0/en
Application filed filed Critical
Publication of BR9510490A publication Critical patent/BR9510490A/pt
Publication of BR9510490B1 publication Critical patent/BR9510490B1/pt

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
BRPI9510490-9A 1994-12-23 1995-12-21 composição farmacêutica combinada de dois componentes estruturada para uso em um hospedeiro. BR9510490B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9426192.2A GB9426192D0 (en) 1994-12-23 1994-12-23 Chemical compounds
GBGB9516810.0A GB9516810D0 (en) 1995-08-16 1995-08-16 Chemical compounds
PCT/GB1995/002991 WO1996020011A1 (en) 1994-12-23 1995-12-21 Chemical compounds

Publications (2)

Publication Number Publication Date
BR9510490A BR9510490A (pt) 1998-01-13
BR9510490B1 true BR9510490B1 (pt) 2010-10-05

Family

ID=26306259

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9510490-9A BR9510490B1 (pt) 1994-12-23 1995-12-21 composição farmacêutica combinada de dois componentes estruturada para uso em um hospedeiro.

Country Status (23)

Country Link
US (1) US5985281A (pt)
EP (1) EP0806964B1 (pt)
JP (1) JP3805365B2 (pt)
KR (1) KR100270650B1 (pt)
CN (1) CN1095677C (pt)
AT (1) ATE222124T1 (pt)
AU (1) AU701916B2 (pt)
BR (1) BR9510490B1 (pt)
CA (1) CA2205091A1 (pt)
CZ (1) CZ195297A3 (pt)
DE (1) DE69527805T2 (pt)
ES (1) ES2181805T3 (pt)
FI (1) FI972683A0 (pt)
HU (1) HUT77450A (pt)
IL (1) IL116511A0 (pt)
MX (1) MX9704575A (pt)
NO (1) NO972882L (pt)
NZ (1) NZ297529A (pt)
PL (1) PL184031B1 (pt)
RU (1) RU2189251C2 (pt)
SK (1) SK80997A3 (pt)
TR (1) TR199501654A2 (pt)
WO (1) WO1996020011A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436691B1 (en) * 1995-08-16 2002-08-20 Zeneca Limited Chemical compounds
TW406454B (en) 1996-10-10 2000-09-21 Berg Tech Inc High density connector and method of manufacture
WO1998035988A1 (en) * 1997-02-14 1998-08-20 Zeneca Limited Proteins
GB9703201D0 (en) * 1997-02-15 1997-04-02 Zeneca Ltd Chemical compounds
GB9709421D0 (en) * 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
AU763628B2 (en) * 1998-09-18 2003-07-31 Immunomedics Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
US20040117863A1 (en) * 1998-09-18 2004-06-17 Edge Michael D. Transgenically produced fusion proteins
US6361774B1 (en) 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
RU2002110121A (ru) * 1999-09-17 2004-03-10 Джитиси Байотерапьютикс, Инк. (Us) Слитые белки, полученные трансгенным способом
EP1565564A4 (en) * 2002-11-27 2006-06-07 Gtc Biotherapeutics Inc STILK-STABILIZED ANTIBODIES PRODUCED IN MILK AND METHOD FOR THE MANUFACTURE THEREOF
US20080019905A9 (en) * 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
EP2388272A1 (en) * 2005-10-21 2011-11-23 GTC Biotherapeutics, Inc. Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
EP2037954A4 (en) * 2006-06-20 2011-09-14 Janssen Pharmaceutica Nv METHOD FOR MODULATING PHARMACOKINETICS AND METABOLISM OF THERAPEUTIC USE
US20080031866A1 (en) * 2006-06-20 2008-02-07 Eichenbaum Gary M Method for modulating the pharmacokinetics and metabolism of a therapeutic agent
EP2077991B1 (en) 2006-10-03 2014-02-26 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of mustards and related compounds with very high skin penetration rates
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
WO2009134389A2 (en) * 2008-05-01 2009-11-05 Gtc Biotherapeutics, Inc. An anti-cd137 antibody as an agent in the treatment of inflammatory conditions
US10745492B1 (en) 2019-04-03 2020-08-18 Ark Diagnostics, Inc. Antibodies to symmetrically dimethylated arginine analytes and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5632990A (en) * 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
DK0454783T3 (da) * 1989-01-23 1995-10-16 Akzo Nobel Nv Sted-specifik in vivo aktivering af terapeutiske lægemidler
US5433955A (en) * 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
JP3431146B2 (ja) * 1992-01-30 2003-07-28 ジェンザイム・リミテッド 改変した酵素によるキラル合成
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
US5389537A (en) * 1994-01-21 1995-02-14 Wisconsin Alumni Research Foundation Nuclease having altered specificity

Also Published As

Publication number Publication date
IL116511A0 (en) 1996-07-23
RU2189251C2 (ru) 2002-09-20
CA2205091A1 (en) 1996-07-04
JPH10511547A (ja) 1998-11-10
KR100270650B1 (ko) 2000-11-01
PL320964A1 (en) 1997-11-24
NZ297529A (en) 1999-07-29
DE69527805D1 (de) 2002-09-19
DE69527805T2 (de) 2003-04-24
SK80997A3 (en) 1998-02-04
BR9510490A (pt) 1998-01-13
ES2181805T3 (es) 2003-03-01
MX9704575A (es) 1997-10-31
CZ195297A3 (en) 1997-12-17
NO972882L (no) 1997-08-19
US5985281A (en) 1999-11-16
FI972683A (fi) 1997-06-19
FI972683A0 (fi) 1997-06-19
CN1095677C (zh) 2002-12-11
WO1996020011A1 (en) 1996-07-04
PL184031B1 (pl) 2002-08-30
TR199501654A3 (pt) 1996-07-21
CN1171054A (zh) 1998-01-21
EP0806964A1 (en) 1997-11-19
AU701916B2 (en) 1999-02-11
EP0806964B1 (en) 2002-08-14
NO972882D0 (no) 1997-06-20
TR199501654A2 (tr) 1996-07-21
AU4269796A (en) 1996-07-19
JP3805365B2 (ja) 2006-08-02
HUT77450A (hu) 1998-04-28
ATE222124T1 (de) 2002-08-15

Similar Documents

Publication Publication Date Title
BR9510490B1 (pt) composição farmacêutica combinada de dois componentes estruturada para uso em um hospedeiro.
BRPI0411505A (pt) uso de um composto, método para modular a resposta imune de um indivìduo, composição farmacêutica, vacina, complexo, e, kit para a captura de uma molécula biologicamente ativa
BR0113491A (pt) Polinucleotìdeo e polipeptìdeo isolados, vetor de expressão, célula hospedeira, proteìna de fusão, métodos para estimular e/ou expandir células t especìficas para uma protéina de tumor, para estimular uma resposta imune em um paciente, para o tratamento de um câncer em um paciente e para inibir o desenvolvimento de um câncer em um paciente, população de célula t isolada, composição, e, uso de um componente.
BRPI0010612B8 (pt) vacinas
PL350658A1 (en) Medical preparations for the treatment of alpha−galactosidase a deficiency
WO2003030934A3 (en) Cpg formulations and related methods
AU4093799A (en) Bifunctional molecules and therapies based thereon
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
BRPI0511420A (pt) fosforodiamidatos de sulfoniletila
AU3057297A (en) Targeted combination immunotherapy of cancer
ATE197903T1 (de) Peptid-kohlenwasserstoff konjugate, welche t-zell immunität bewirken
BR0115162A (pt) Tratamentos antitumorais eficazes
BR0108728A (pt) Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
NO980317L (no) Anvendelse av Calendula-glykosider for behandling av psoriasis
AU1206292A (en) Therapeutic agents for the treatment of multidrug resistance to cancers
SE8700467L (sv) Monoklonala humanantikroppberedningar som er korsprotektiva
BR9610050A (pt) Conjugado,sitemas de dois componentes combinados destinados a uso em um hospedeiro, compostos ou um sal destes famaceuticamente aceitavel,enzima,sequencia de polinucleotìdeos e de02 nucleotìdeos,vetor, célula hospedeira,processos de producão de uma enzima e de um conjugado e de tratamento de célulasneoplásticas em um hospedeiro,composicão farmaceutica e plasmìdeo
BR0008305A (pt) Utilização de uma proteìna ompa de enterobactéria, ou de um de seus fragmentos e composição farmacêutica
DK1161250T3 (da) Immunstimulerende bakteriemembranfraktioner i cancerbehandling
AR014884A1 (es) Uso de un conjugado de angiotensina inmunogenico y composicion farmaceutica
WO2000078800A3 (en) Combined decorin binding protein and outer surface protein compositions and methods of use
BR9714945A (pt) Composição topicamente aplicável para introdução de fármacos peptidaceosos em organismos vivos
PT100155A (pt) Uso de compostos analogos da camptotecina na obtencao de um medicamento para uso no tratamento do carcinoma das celulas nao pequenas do pulmao e composicoes farmaceuticas
BR112023009912A2 (pt) Anticorpo anti-claudina 18.2 e conjugado anticorpo-fármaco do mesmo

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: COM BASE NO ARTIGO 8O DA LPI DE 9279/96 COMBINADO COM O ARTIGO 13 DA LPI DE 9279/96, DECIDIMOS PELO INDEFERIMENTO DO PRESENTE PEDIDO.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B25D Requested change of name of applicant approved

Owner name: SYNGENTA LIMITED (GB)

Free format text: ALTERADO DE: ZENECA LIMITED

B25G Requested change of headquarter approved

Owner name: SYNGENTA LIMITED (GB)

Free format text: ANOTADAS AS ALTERACOES DE SEDE, CONFORME SOLICITADO NA PETICAO NO 020070050229/RJ DE 19/04/2007.

B25A Requested transfer of rights approved

Owner name: ASTRAZENECA UK LIMITED (GB)

Free format text: TRANSFERIDO DE: SYNGENTA LIMITED

B25A Requested transfer of rights approved

Owner name: LONDON BIOTECHNOLOGY LIMITED (GB)

Free format text: TRANSFERIDO DE: ASTRAZENECA UK LIMITED

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/10/2010, OBSERVADAS AS CONDICOES LEGAIS.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.061577/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132353-78.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO, LONDON BIOTECHNOLOGY LIMITED, MERCK SHARP AND DOHME, N.V. ORGANON, NICOX S.A.

B24C Patent annual fee: request for for restoration

Free format text: REFERENTE A 18A ANUIDADE.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time
B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: MANUTENCAO DA EXTINCAO - ART. 78 INCISO IV DA LPI

B15K Others concerning applications: alteration of classification

Ipc: B82Y 5/00 (2011.01), A61K 47/68 (2017.0

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.061577/2013-10 SECAO JUDICIARIA DO RIO DE JANEIRO 9A VARA FEDERAL DO RIO DE JANEIRO PROCESSO: NO0132353-78.2013.4.02.5101APELANTE: MERCK SHARP AND DOHME CORP E OUTROS APELADO: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI DECISAO: A CONTROVERSIA SOBRE O PRAZO DE VIGENCIA DAS PATENTES MAILBOX FOI DEVIDAMENTE APRECIADA POR ESTE TRIBUNAL NO AMBITO DAS TURMAS ESPECIALIZADAS, ASSIM COMO TAMBEM NO DA SECAO, ALEM DO E. STJ, TENDO SIDO CONSOLIDADO O ENTENDIMENTO NO SENTIDO DE QUE O PARAGRAFO UNICO DO ARTIGO 40 DA LEI NO9.279/96 NAO SE APLICA AS PATENTES ?MAILBOX?, DIANTE DA LIMITACAO ESTABELECIDA PELO ARTIGO 229, PARAGRAFO UNICO, DA MESMA LEI DEVENDO SER APLICADO O PRAZO DE VIGE